Vaishali Pharma Ltd, a leading Mumbai-based pharmaceutical company, has announced a 1:1 bonus issue and a 1:5 stock split, aiming to reward shareholders and boost liquidity. The company’s board approved these measures in a meeting held on August 28, 2024, pending regulatory and shareholder approvals. Under the stock split, one equity share of ₹10 face value will be subdivided into five shares of ₹2 each.
This move aligns with the company’s vision to enhance shareholder trust while expanding its equity base. Vaishali Pharma recently secured 19 registrations in regions including Africa and Latin America, expected to add ₹100 million to its revenue.
The company’s Q1FY25 financial performance reflects a 34.70% rise in sales, reaching ₹18.08 crore. Commenting on the development, Chairman Atul Vasani stated, “The stock split and bonus issue are part of our long-term strategy to reward shareholders and drive innovation.”
